Flavonoids as inhibitors of human carbonyl reductase 1

Chemico-Biological Interactions

Volumn 174, Issue 2, 2008, Pages 98-108

  Carlquist, Magnus ^a   Frejd, Torbjörn ^a   Gorwa Grauslund, Marie F ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Adriamycin; Anthracyclines; CBR1; Daunorubicin; Doxorubicin; Flavonoids; Human carbonyl reductase 1; IC50; Mixed inhibition; Rutin; Saccharomyces cerevisiae

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBONYL REDUCTASE; CARBONYL REDUCTASE 1; DAUNORUBICIN; DOXORUBICIN; FLAVONOID; QUERCETIN; QUERCITRIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RUTOSIDE;

ARTICLE; BINDING SITE; CATALYSIS; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; IC 50; INHIBITION KINETICS; MICHAELIS MENTEN KINETICS; NONHUMAN; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; STRUCTURE ACTIVITY RELATION;

ALCOHOL OXIDOREDUCTASES; ANTIBIOTICS, ANTINEOPLASTIC; BINDING SITES; DAUNORUBICIN; ENZYME INHIBITORS; FLAVONOIDS; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, MOLECULAR; PLANT EXTRACTS; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE, TERTIARY; QUERCETIN; RUTIN; SACCHAROMYCES CEREVISIAE; SUBSTRATE SPECIFICITY; TRANSFECTION;

SACCHAROMYCES CEREVISIAE;

EID: 46049109896     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.05.021     Document Type: Article

References (39)

1. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 2 (2004) 185-229
2. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin. Oncol. 19 6 (1992) 670-686
3. Forrest G.L., Gonzalez B., Tseng W., Li X., and Mann J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res. 60 18 (2000) 5158-5164
4. Olson L.E., Bedja D., Alvey S.J., Cardounel A.J., Gabrielson K.L., and Reeves R.H. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res. 63 20 (2003) 6602-6606
5. Kuffel M.J., Reid J.M., and Ames M.M. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother. Pharmacol. 30 1 (1992) 51-57
6. Ax W., Soldan M., Koch L., and Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol. 59 3 (2000) 293-300
7. Soldan M., Netter K.J., and Maser E. Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Biochem. Pharmacol. 51 2 (1996) 117-123
8. Gonzalez B., Akman S., Doroshow J., Rivera H., Kaplan W.D., and Forrest G.L. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res. 55 20 (1995) 4646-4650
9. Plebuch M., Soldan M., Hungerer C., Koch L., and Maser E. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett. 255 1 (2007) 49-56
10. Mordente A., Meucci E., Martorana G.E., Giardina B., and Minotti G. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52 1/2 (2001) 83-88
11. X. Zhang, R.D. Olson, G.M. Walsh, 13-Deoxyanthracycline derivates and processes for preparing them, 1999, Patent WO9908687.
12. Lee E.K., Regenold W.T., and Shapiro P. Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anticancer Drugs 13 8 (2002) 859-868
13. Oppermann U. Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 293-322
14. Matsunaga T., Shintani S., and Hara A. Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab. Pharmacokinet. 21 1 (2006) 1-18
15. Forrest G.L., and Gonzalez B. Carbonyl reductase. Chem. Biol. Interact. 129 1-2 (2000) 21-40
16. Ohara H., Miyabe Y., Deyashiki Y., Matsuura K., and Hara A. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem. Pharmacol. 50 2 (1995) 221-227
17. Wermuth B. Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase. J. Biol. Chem. 256 3 (1981) 1206-1213
18. Forrest G.L., Akman S., Doroshow J., Rivera H., and Kaplan W.D. Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity. Mol. Pharmacol. 40 4 (1991) 502-507
19. Costantino L., Rastelli G., Vianello P., Cignarella G., and Barlocco D. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. Med. Res. Rev. 19 1 (1999) 3-23
20. Oka M., and Kato N. Aldose reductase inhibitors. J. Enzyme Inhib. 16 6 (2001) 465-473
21. Mylari B.L., Armento S.J., Beebe D.A., Conn E.L., Coutcher J.B., Dina M.S., O'Gorman M.T., Linhares M.C., Martin W.H., Oates P.J., Tess D.A., Withbroe G.J., and Zembrowski W.J. A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners. J. Med. Chem. 48 20 (2005) 6326-6339
22. Sun W., Oates P.J., Coutcher J.B., Gerhardinger C., and Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 55 10 (2006) 2757-2762
23. Rosemond M.J., and Walsh J.S. Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab. Rev. 36 2 (2004) 335-361
24. Varma S.D., Mikuni I., and Kinoshita J.H. Flavonoids as inhibitors of lens aldose reductase. Science 188 4194 (1975) 1215-1216
25. Tanaka M., Bateman R., Rauh D., Vaisberg E., Ramachandani S., Zhang C., Hansen K.C., Burlingame A.L., Trautman J.K., Shokat K.M., and Adams C.L. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 3 5 (2005) e128
26. Mordente A., Minotti G., Martorana G.E., Silvestrini A., Giardina B., and Meucci E. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem. Pharmacol. 66 6 (2003) 989-998
27. Husken B.C., de Jong J., Beekman B., Onderwater R.C., van der Vijgh W.J., and Bast A. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids. Cancer Chemother. Pharmacol. 37 1/2 (1995) 55-62
28. Sambrook J., Fritch E., and Maniatis T. Molecular Cloning: A Laboratory Manual (1989), Cold Spring harbor Laboratory Press, Cold Spring Harbor, New York
29. Mumberg D., Muller R., and Funk M. Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene 156 1 (1995) 119-122
30. Inoue H., Nojima H., and Okayama H. High efficiency transformation of Escherichia coli with plasmids. Gene 96 1 (1990) 23-28
31. Gietz R.D., Schiestl R.H., Willems A.R., and Woods R.A. Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast 11 4 (1995) 355-360
32. Cornish-Bowden A. Fundamentals of Enzyme Kinetics (2004), Portland Press
33. Holder S., Zemskova M., Zhang C., Tabrizizad M., Bremer R., Neidigh J.W., and Lilly M.B. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol. Cancer Ther. 6 1 (2007) 163-172
34. Komoto J., Yamada T., Watanabe K., and Takusagawa F. Crystal structure of human prostaglandin F synthase (AKR1C3). Biochemistry 43 8 (2004) 2188-2198
35. Slupe A., Williams B., Larson C., Lee L.M., Primbs T., Bruesch A.J., Bjorklund C., Warner D.L., Peloquin J., Shadle S.E., Gambliel H.A., Cusack B.J., Olson R.D., and Charlier Jr. H.A. Reduction of 13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl reductase. Cardiovasc. Toxicol. 5 4 (2005) 365-376
36. Bohren K.M., von Wartburg J.P., and Wermuth B. Kinetics of carbonyl reductase from human brain. Biochem. J. 244 1 (1987) 165-171
37. Gonzalez-Covarrubias V., Ghosh D., Lakhman S.S., Pendyala L., and Blanco J.G. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab. Dispos. 35 6 (2007) 973-980
38. Tinguely J.N., and Wermuth B. Identification of the reactive cysteine residue (Cys227) in human carbonyl reductase. Eur. J. Biochem. 260 1 (1999) 9-14
39. Bohren K.M., Wermuth B., Harrison D., Ringe D., Petsko G.A., and Gabbay K.H. Expression, crystallization and preliminary crystallographic analysis of human carbonyl reductase. J. Mol. Biol. 244 5 (1994) 659-664